MetaCap

Heartbeam (BEAT) vs Polyrizon (PLRZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Polyrizon (PLRZ) has outperformed Heartbeam (BEAT) over the past year, gaining 23.2% versus a loss of 72.9%. Heartbeam is the larger company by market cap ($27.3 million vs $22.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BEAT-72.85%PLRZ+23.19%
+149%+29%-91%
Oct 8, 20251 yearOct 8, 2026
BEAT-80.37%PLRZ-99.49%
+74%-17%-108%
Oct 28, 20245 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BEAT versus PLRZ key metrics
MetricBEATPLRZ
Share price$0.4851$9.39
Market cap$27.33M$22.80M
1-day change-0.74%+5.86%
YTD return-79.64%+4.48%
1-year return-72.85%+23.19%
EPS (TTM)$-0.50$-4.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$4.00$18.20
52-week low$0.355$2.88
Distance from 52-week high-87.87%-48.41%
Analyst consensusbuy—
Avg. price target upside+621.50%—
Average volume7.37M60.55K
Shares outstanding56.35M2.43M
Employees162
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLRZ has outperformed BEAT by 96.0 percentage points over the past year.

About Heartbeam

BEAT stock →

HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility.

Health Care · Medical/Dental Instruments · 16 employees

About Polyrizon

PLRZ stock →

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.

Health Care · Medical/Dental Instruments · 2 employees

BEAT vs PLRZ FAQ

Which is bigger, Heartbeam or Polyrizon?

Heartbeam (BEAT) is larger, with a market capitalization of $27.33M compared with $22.80M for Polyrizon (PLRZ).

Which stock has performed better over the past year, BEAT or PLRZ?

PLRZ returned +23.19% over the past 12 months, compared with -72.85% for BEAT (price return, excluding dividends). Past performance does not predict future results.

Are Heartbeam and Polyrizon in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons